PCN166 TRAZTUZUMAB ON ADJUVANT BREAST CANCER TREATMENT: EVIDENCE SYNTHESIS AND A HEALTH TECHNOLOGY EVALUATION

  • Clark O
  • Paladini L
  • Clark L
  • et al.
N/ACitations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

OBJECTIVES: The use of Trastuzumab (T) for the adjuvant treatment of breast cancer patients (BCP) has been tested in clinical trials. Our goal is to perform a health technology evaluation in order to stablish if the scientific evidences are strong enough to support the use of T and to compare its cost-effectiveness ratio (CER) with other treatments covered by the public sector in Brazil. METHODS: We performed a literature search, looking for randomized controlled clinical trials (RCTs), systematic reviews (SR), guidelines, pharmacoeconomic analysis and endorsements from regulatory agencies on the use of T for BCP. RESULTS: We found five RCTs, three SR, six guidelines / health technology assessments and three endorsements from regulatory agencies. Four RCTs tested Trastuzumab 2 mg/kg/week or 6 mg/kg/ every 3 weeks during one year, in patients with tumors >= 1 cm. All of these showed a 50% reduction on risk of relapse and a 40% reduction in death risk. SR confirmed these findings. The only study that did not show a survival gain, used T for only nine weeks. Guidelines and regulatory agencies recomend the use of T for one year. On the pharmacoeconomic perspective, T has a CER similar or better than other procedures covered by the public sector in Brazil, such as heart transplant, tacrolimus for kidney transplantation, ribavirin plus peg-interferon for C hepatitis and bone marrow transplant. These procedures have a CER betwen US$35,000 and US$45,000 / QALY (or above). The CER of adjuvant T is around US$20,000/QALY. CONCLUSIONS: Trastuzumab is indicated for the adjuvant treatment of BCP, and must be considered as standard treatment for these patients. Also, from a pharmacoeconomic point of view, it's CER is similiar to other medical interventions covered by the Brazilian health care public system.

Cite

CITATION STYLE

APA

Clark, O., Paladini, L., Clark, L., Pegoretti, B., Faleiros, E., & Engel, T. (2009). PCN166 TRAZTUZUMAB ON ADJUVANT BREAST CANCER TREATMENT: EVIDENCE SYNTHESIS AND A HEALTH TECHNOLOGY EVALUATION. Value in Health, 12(7), A289. https://doi.org/10.1016/s1098-3015(10)74416-8

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free